Pharsight

Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device
Nov, 2024

(1 year, 1 month from now)

US8752543 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(2 years from now)

US8062264 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(2 years from now)

US8347879 GLAXOSMITHKLINE CONS Fluid dispensing device
Jul, 2028

(4 years from now)

US8147461 GLAXOSMITHKLINE CONS Fluid dispensing device
Oct, 2028

(5 years from now)

Flonase Sensimist Allergy Relief is owned by Glaxosmithkline Cons.

Flonase Sensimist Allergy Relief contains Fluticasone Furoate.

Flonase Sensimist Allergy Relief has a total of 5 drug patents out of which 0 drug patents have expired.

Flonase Sensimist Allergy Relief was authorised for market use on 02 August, 2016.

Flonase Sensimist Allergy Relief is available in spray, metered;nasal dosage forms.

The generics of Flonase Sensimist Allergy Relief are possible to be released after 15 October, 2028.

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic